GlassScriptPhysician profile
David Duong
NPI 1356538904
$64,229.51
in general payments reported to CMS, 2019-2025
43 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $1,757 · 2021: $1,332 · 2022: $746 · 2023: $4,806 · 2024: $34K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $9,210 · Travel and Lodging: $8,716 · Food and Beverage: $6,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,053.88 |
| Consulting Fee | $9,210.00 |
| Travel and Lodging | $8,716.05 |
| Food and Beverage | $6,178.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45,323.58 | 2023-2025 | Rivfloza |
| Calyxo, INC. | $9,873.91 | 2024-2025 | Cvac Aspiration System |
| Olympus America INC. | $1,026.98 | 2021-2025 | Itind System |
| Olympus Corporation of The Americas | $859.30 | 2020 | |
| Axonics, INC. | $686.68 | 2020-2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $685.89 | 2019-2022 | |
| Coloplast Corp | $642.08 | 2023-2025 | Coloplast Tfl Drive, Porges Coloplast |
| Urogen Pharma, INC. | $571.65 | 2021-2025 | Jelmyto |
| Pfizer INC. | $549.74 | 2022-2025 | |
| Astellas Pharma US INC | $470.68 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $375.75 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $329.49 | 2020-2025 | Lithovue, Axonics, Lumenis Pulse 120h |
| Blue Earth Diagnostics | $302.38 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $301.70 | 2019-2021 | |
| Cipla USA INC. | $267.27 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$256,451.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.